In vivo molecular imaging in the "transparent" near-infrared II (NIR-II) window has demonstrated impressive benefits in reaching millimeter penetration depths with high specificity and imaging quality. Previous NIR-II molecular imaging generally relied on high hepatic uptake fluorophores with an unclear mechanism and antibody-derived conjugates, suffering from inevitable nonspecific retention in the main organs/skin with a relatively low signal-to-background ratio. It is still challenging to synthesize a NIR-II fluorophore with both high quantum yield and minimal liver-retention feature. Herein, we identified the structural design and excretion mechanism of novel NIR-II fluorophores for NIR-II molecular imaging with an extremely clean background. With the optimized renally excreted fluorophore-peptide conjugates, superior NIR-II targeting imaging was accompanied by the improved signal-to-background ratio during tumor detection with reducing off-target tissue exposure. An unprecedented NIR-II imaging-guided microsurgery was achieved using such an imaging platform, which provides us with a great preclinical example to accelerate the potential clinical translation of NIR-II imaging.
Introduction
Biological imaging with uorescence in the NIR-II region ranging from 1000 to 1700 nm (ref. [1] [2] [3] [4] benets from reduced body autouorescence and light scattering, allowing for enhanced sub-centimeter penetration into biological systems. [5] [6] [7] [8] [9] [10] [11] To achieve NIR-II molecular imaging with high contrast for preclinical/clinical use, both the uorophore and conjugated targeting probe need to be renally excreted with low retention in normal tissues. [12] [13] [14] Compared to antibodies and hormones, peptides provide high binding affinity, low immunogenicity and faster body clearance. 15, 16 So far, many kinds of peptides have been recognized and developed for specic tumor biomarkers, 17 and over 150 peptides in active development have entered human clinical studies. 18 For example, arginylglycylaspartic acid (RGD) motifs have been widely utilized as imagingguided diagnostic probes, [19] [20] [21] and radioactive isotope modied targeting peptides can reach high tumor-to-normal tissue (T/NT) ratios in positron emission tomography (PET) imaging.
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Fluorescent probes derived from specic peptides have been used clinically in NIR-I imaging-guided tumor surgery. 24 Fluorescence imaging possesses an advantage in both spatial and temporal resolutions, 25, 26 and the bottleneck caused by penetration issues could be improved by imaging at longer wavelengths. [27] [28] [29] [30] Renally excreted conjugates in the NIR-II window prot from both the low uptake of normal tissue/immune systems and reduced tissue autouorescence/scattering. As a result, NIR-II peptide conjugated dyes with high quantum yields and renal excretion ability afford great penetration depths and high signal/background ratios for preclinical and clinical settings. So far, NIR-II uorophores have expanded to inorganic materials, polymer encapsulated organic dyes and water-soluble molecular uorophores, 29, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] which mostly suffer from high uptake and long-term retention in the immune system, causing considerable safety concerns in terms of clinical applications. It is of great importance to exploit bright NIR-II uorophores with both high quantum yields and fast excretion ability.
Although several NIR-II uorophores with renal clearance ability have been exploited, 16, 35, 46, 52 they exhibit relatively low NIR-II quantum yields. Further, much less is known about the excretion mechanism in NIR-II uorophores. It is generally considered that a small size less than the renal cutoff is one of the key factors to afford renal excretion ability. [52] [53] [54] [55] [56] However, the experimental result showed that size is not the single determining factor that leads to such renal excretion. 57 Other comparatively unexplored parameters limit the development of NIR-II uorophores with renal excretion ability, and we lack a complete understanding of the mechanisms that contribute to renal and hepatobiliary excretion pathways.
Here, we screened and optimized a high-performance NIR-II uorophore, IR-BEMC6P, with rapid renal excretion, minimal hepatic uptake and a relatively high quantum yield (QY) of 1.8%. By systematically comparing IR-BEMC6P and a series of NIR-II uorophores, we found that a NIR-II uorophore with renal excretion ability needs to possess a small size, fast dissociation with proteins, near-neutral functional groups, and low macrophage uptake. We next developed renally excreted targeting peptide-conjugated probes for in vivo NIR-II tumor imaging, exhibiting high tumor specicity and low off-target organ uptake. We further demonstrated that the IR-BEMC6P@peptide conjugate offered a competitive imaging quality to PET imaging with the same targeting peptide, allowing the possibility of NIR-II guided microsurgery. We expect that the renal excretion of NIR-II conjugates will accelerate NIR-II molecular imaging into clinical applications as new therapeutic agents.
Results and discussion
Rational design of minimal liver-uptake and super highcontrast NIR-II uorophores with donor/shielding unit engineering of S-D-A-D-S molecules
We rst synthesized a new NIR-II molecular uorophore, IR-BEMC6P, based on the shielding-donor-acceptor-donorshielding (S-D-A-D-S) structure (Fig. 1a , see the synthesis optimization process and structural characterization in Fig. S1 -S10 †). Benzo [1,2- (Fig. 1a) . Compared to IR-BTMC6P with solely thiophene as the p unit, EDOT can distort the conjugated backbone and lower molecular interactions to reduce non-radiative transitions (Fig. 1b , Tables S1 and S2 †).
57 Dialkoxy substituted benzene modules were introduced as the shielding units, as the stretching dialkoxy chain on the conjugated backbone could prevent intermolecular interactions to enhance QY. Further, the dialkoxy substituted benzene shielding unit can enable renal excretion ability. 52 The termini of the two side chains were modied by polyethylene glycol (PEG) for good biocompatibility, while the two side chains were functionalized with azide groups for bioconjugation. IR-BEMC6P showed an absorption peak at 725 nm, and its uorescence peaked at 1025 nm and ranged from 900 to 1400 nm (Fig. S10 †) . The QY of IR-BEMC6P was determined to be 1.8% with HiPCO SWCNT as the reference uorophore (Table S1 †).
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The screened dialkoxy substituted benzene shielding groups served as a key factor to endow the IR-BEMC6P with renal excretion ability. Although previously studied NIR-II uo-rophores IR-FEP and IR-FGP with uorene as the shielding group exhibited similar quantum yields, 57, 59 they lacked the renal excretion ability and suffered from high liver uptake and long retention (Fig. S11 †) . To conrm the excretion route of IR-BEMC6P, shaved CD-1 mice were intravenously injected with IR-BEMC6P at a dose of 1 mg kg À1 (Fig. 2a) . The blood clearance of IR-BEMC6P was observed with 70% ID per g at 3 minutes post injection (p.i.) and decreased to <1% ID per g at 12 hours p.i. (Fig. S12a †) . The accumulated signal of IR-BEMC6P in the bladder indicated a very fast renal clearance pathway ( Fig. S12b †) , affording the super clean skin/normal tissue background (Fig. 2b ). Biodistribution at 24 h p.i. showed that most organs presented extremely low uorescence signals (Fig. S13a †) . As a result, IR-BEMC6P was proven to be a bright NIR-II imaging contrast agent with fast clearance behavior post-imaging. In vivo toxicity of IR-BEMC6P in the administrated mouse cohorts was evaluated by appearance (Fig. S13b †) , hematology and serum biochemical analysis (Table S3 †) , as well as the pathology analysis of the main organs (Fig. S14 †) . 15 Overall, the IR-BEMC6P uorophore did not cause toxic reactions, demonstrating favorable biocompatibility in both research and clinical workows. 56, 60, 61 Excretion mechanism of NIR-II uorophores Aer observing that IR-BEMC6P is endowed with renal excretion ability, we further aimed to study the relationship between the chemical structure and excretion behavior of this type of S-D-A-D-S dye. Generally, small and hydrophilic molecules are mainly excreted via the kidneys, whereas large and amphipathic molecules are preferentially excreted via the liver.
62 By additionally investigating the whole-body imaging of non-renal excreted IR-FGP and IR-FEP, 57, 59 we conrmed that the S-D-A-D-S dyes with uorene groups suffered from long-term liver retention (Fig. S11 †) . With this preliminary excretion data for S-D-A-D-S dyes, we chose three types of NIR-II dyes, IR-BEMC6P with fast renal excretion, IR-12N3 with fast hepatobiliary clearance, 63 and IR-FEP/IR-FGP with long liver retention, for further investigation.
To understand the excretion mechanism of these types of NIR-II dyes, we tested the size, protein binding affinity, and macrophage uptake of the screened NIR-II dyes. Previous experimental evidence suggested that a small size less than the renal cutoff (5 nm) was one of the most favorable factors to endow organic uorophores with renal excretion ability. 54 In the present study, the size of the renal excretion dye IR-BEMC6P was assuredly found to be less than 5 nm (Table S4 †) , compared to the high liver-uptake dye IR-FGP with a size of over 50 nm. However, the size of another high liver-uptake dye IR-FEP was also found to be less than 5 nm. The deviation of size-controlled excretion pathways indicates that other unexplored parameters rather than size, such as interaction with serum plasma and the immune system, have to be involved. Studying these parameters is likely essential to identify the excretion mechanism of the NIR-II uorophores.
We then studied the interaction with the serum plasma and macrophage of these uorophores. The dyes' binding affinities with albumin (the most abundant protein in plasma) were rst tested. The K d values of IR-BEMC6P and IR-FEP are 1.2 mM and 2.5 nM, respectively, indicating the stronger albumin binding for long-liver-retention dyes. Although IR-12N3 and IR-FGP also showed high binding affinities to albumin in the range of 1-30 mM, both IR-BEMC6P and IR-12N3 showed rapid de-binding behavior (sharp dissociation curves), while the long liver retention dyes IR-FGP/IR-FEP showed very slow de-binding ability (at dissociation curves in Fig. 2c and S15 †). This suggested that fast excretion dyes were primarily transported by serum proteins and could be quickly released when they reached the excretory system. 15 What's more, when we incubated the investigated uorophores with macrophages, IR-FEP and IR-FGP showed a much higher macrophage uptake (99.4% for IR-FEP and 73.6% for IR-FGP) compared to fast excretion dyes (32.4% for IR-BEMC6P and 20.0% for IR-12N3), indicating that long liver-uptake dyes were preferentially endocytosed by macrophages ( Fig. 2d and S16 †) . 64 Finally, we veried that the surface chemistry was also able to affect the renal excretion behaviors. By changing the azide group of IR-BEMC6P to amine and carboxyl groups, the fast renal excretion dyes became high liver-uptake dyes (Fig. S17 †) . Based on the above evidence, we concluded that NIR-uorophores with renal excretion ability possessed small size, near-neutral functional groups, fast dissociation with proteins, and low uptake by macrophages (Fig. 2e) .
NIR-II renally excreted uorophore-peptide conjugates and NIR-II molecular imaging guided microsurgery
We then aimed to develop a high-performance renal-excretion peptide bioconjugate for tumor imaging based on the optimized renal excretion NIR-II uorophore and targeting peptides. Although the NIR-II uorophore-peptide conjugate has been reported with renally excreted behavior, 16 the liver also had non-negligible uptake given the unoptimizable structural design. We rst conjugated IR-BEMC6P to an RGD peptide and proved the superior excretion behavior of the IR-BEMC6P@RGD conjugate p.i. (Fig. S18 †) . To test the efficiency of conjugate targeting, we investigated molecular imaging in vivo with U87 tumor-bearing mice. The tumor mice were intravenously injected with IR-BEMC6P@RGD probes in PBS. NIR-II imaging over 1200 nm indicated that IR-BEMC6P@RGD accumulated in the U87 tumor in less than 1 h (Fig. 3a) , with the T/NT ratio reaching a maximum of $9 at 6 h p.i. (Fig. 3b) and low accumulation in other organs (Fig. 3c) . 46 In contrast, the nontargeted IR-BEMC6P uorophore showed a relatively weaker signal in the U87 tumor and the maximum T/NT ratio was less than $4 (Fig. S19 †) , due to the nonspecic accumulation of the free IR-BEMC6P.
We further investigated the advantage of NIR-II bioimaging by imaging the brain vessels in C57 mice with intact skin/scalp using either ICG or IR-BEMC6P, respectively (Fig. 3d-f) . 53 To demonstrate the benet of the developed renal excretion conjugate in NIR-II molecular imaging, a glioblastoma brain tumor was surgically inoculated through the U87MG cells in the le hemisphere of the mouse brain. By intravenously injecting IR-BEMC6P@RGD, the NIR-II imaging of the brain tumor through a non-invasive route was performed through both the scalp and the skull. 6-12 h aer administration of IR-BEMC6P@RGD, the tumor was distinguished with a T/NT ratio of $6 with NIR-II whole body imaging (Fig. 3g) . By subsequently injecting PbS@PEG quantum dots with over 1500 nm emission, 65 two-color imaging of both the brain tumor and vessel was obtained at the same time, affording multicolor live molecular imaging across the NIR-II window in a deep tumor model.
We subsequently used the developed strategy to improve the imaging contrast of the octreotate (TATE) peptide. TATE has somatostatin receptors (SSTRs) in gastroenteropancreatic neuroendocrine tumors, in which PET imaging is usually applied with a T/NT around 6, given the high normal tissue signal (Fig. 4a and b) . 15 The NIR-II conjugate IR-BEMC6P@TATE was synthesized with a TATE peptide containing a Dde protecting group (Fig. 4c) . The renal excretion ability of IR-BEMC6P@TATE was conrmed by intravenous injection of IR-BEMC6P@TATE in CD-1 mice with high signal in the bladder but very low signal in the liver (Fig. S20 †) . The IR-BEMC6P@TATE was then injected through the tail vein in the immune-decient mice bearing xenogra AR42J tumors. The tumor uorescence distinctly showed up at 1 h p.i., followed by the T/NT ratio reaching $10 at 3 h p.i. (Fig. 4e-f) . The improved T/NT ratio compared to PET imaging indicates that such a renal excretion conjugate truly beneted from the reduced normal tissue exposure of the conjugate. By injecting a blocking dose of the free, unconjugated TATE together with the IR-BEMC6P@TATE, a very low tumor signal proved the specicity of IR-BEMC6P@TATE on the AR42J tumor model (Fig. 4g) . Further, we performed a tumor excision surgery under both NIR-II imaging and white light guidance (Fig. 4d) . White light was selected for less interference with NIR-II monitoring, and the NIR-II imaging allowed for clear distinction of the tumor margin (Fig. 4h and i) . Moreover, NIR-II guided microsurgery was additionally performed utilizing an IRBEMC6P@follicle-stimulating hormone (FSH) conjugate, allowing us to cut single follicles that are hundreds of mm in size (Fig. S21 †) . Only mild alterations in behavior post-surgery were observed, indicating the high safety of micro-surgery. Although uorescence-guided surgery was achieved in the NIR-I systems, 67 it is still critically important to further improve the detection depth and sensitivity, to yield a comprehensive uorescence-guided platform with adjustable imaging speed (real-time) and contrast (S/B ratio), and multi-targeted imaging for visualizing complex diseases simultaneously.
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Conclusions
In summary, we developed a minimal hepatic-uptake NIR-II dye (IR-BEMC6P) with enhanced QY and derived renal excretion peptide conjugations. The excretion mechanism was exploited through comprehensive factors, and we found that NIR-II u-orophores with renal excretion ability possessed small size, near-neutral functional groups, fast de-binding with proteins, and low uptake by macrophages. This well-established rule for excretion behavior will guide future NIR-II dye synthesis and enrich the NIR-II uorophore library with the clinical choice of NIR-II imaging, as one of the important features of potential NIR uorophores for clinically translatable imaging is timely clearance from the body with minimum retention in major organs aer administration. 5 The renal excretion uorophore derived peptide-dye conjugate provided efficient tumor targeting ability in mice with a high T/NT ratio in two different tumor models, affording great ability for NIR-II guided microsurgery. Importantly, the peptide IR-BEMC6P@(RGD, TATE) probes were rapidly renally excreted, in sharp contrast to long-term liver accumulation of typical antibody-dye conjugates. These rapidly excreted, highly safe integrin/somatostatin receptor targeting NIR-II probes will accelerate the clinical translation of NIR-II molecular imaging in cancer diagnosis and imaging navigation therapy.
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